GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FluoroPharma Medical Inc (OTCPK:FPMI) » Definitions » Asset Turnover

FluoroPharma Medical (FluoroPharma Medical) Asset Turnover : 0.00 (As of Dec. 2016)


View and export this data going back to 2008. Start your Free Trial

What is FluoroPharma Medical Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. FluoroPharma Medical's Revenue for the three months ended in Dec. 2016 was $0.00 Mil. FluoroPharma Medical's Total Assets for the quarter that ended in Dec. 2016 was $0.36 Mil. Therefore, FluoroPharma Medical's Asset Turnover for the quarter that ended in Dec. 2016 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. FluoroPharma Medical's annualized ROE % for the quarter that ended in Dec. 2016 was 5.05%. It is also linked to ROA % through Du Pont Formula. FluoroPharma Medical's annualized ROA % for the quarter that ended in Dec. 2016 was -140.72%.


FluoroPharma Medical Asset Turnover Historical Data

The historical data trend for FluoroPharma Medical's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FluoroPharma Medical Asset Turnover Chart

FluoroPharma Medical Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

FluoroPharma Medical Quarterly Data
Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of FluoroPharma Medical's Asset Turnover

For the Biotechnology subindustry, FluoroPharma Medical's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


FluoroPharma Medical's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, FluoroPharma Medical's Asset Turnover distribution charts can be found below:

* The bar in red indicates where FluoroPharma Medical's Asset Turnover falls into.



FluoroPharma Medical Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

FluoroPharma Medical's Asset Turnover for the fiscal year that ended in Dec. 2016 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2016 )/( (Total Assets (A: Dec. 2015 )+Total Assets (A: Dec. 2016 ))/ count )
=0/( (0.839+0.335)/ 2 )
=0/0.587
=0.00

FluoroPharma Medical's Asset Turnover for the quarter that ended in Dec. 2016 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2016 )/( (Total Assets (Q: Sep. 2016 )+Total Assets (Q: Dec. 2016 ))/ count )
=0/( (0.387+0.335)/ 2 )
=0/0.361
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


FluoroPharma Medical  (OTCPK:FPMI) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

FluoroPharma Medical's annulized ROE % for the quarter that ended in Dec. 2016 is

ROE %**(Q: Dec. 2016 )
=Net Income/Total Stockholders Equity
=-0.508/-10.0555
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-0.508 / 0)*(0 / 0.361)*(0.361/ -10.0555)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*-0.0359
=ROA %*Equity Multiplier
=-140.72 %*-0.0359
=5.05 %

Note: The Net Income data used here is four times the quarterly (Dec. 2016) net income data. The Revenue data used here is four times the quarterly (Dec. 2016) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

FluoroPharma Medical's annulized ROA % for the quarter that ended in Dec. 2016 is

ROA %(Q: Dec. 2016 )
=Net Income/Total Assets
=-0.508/0.361
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-0.508 / 0)*(0 / 0.361)
=Net Margin %*Asset Turnover
= %*0
=-140.72 %

Note: The Net Income data used here is four times the quarterly (Dec. 2016) net income data. The Revenue data used here is four times the quarterly (Dec. 2016) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


FluoroPharma Medical Asset Turnover Related Terms

Thank you for viewing the detailed overview of FluoroPharma Medical's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


FluoroPharma Medical (FluoroPharma Medical) Business Description

Traded in Other Exchanges
N/A
Address
8 Hillside Avenue, Suite 108, Montclair, NJ, USA, 07042
FluoroPharma Medical Inc is a US-based biopharmaceutical company. It specializes in developing and commercializing molecular imaging pharmaceuticals with initial applications in the area of cardiology. The company focuses on the development of novel cardiovascular imaging agents which detect and assess acute and chronic forms of coronary artery disease (CAD). The company's clinical-stage molecular imaging pharmaceutical product candidates are 18-F TPP (BFPET) and 18-F FCPHA (CardioPET). The 18-F TPP is designed for use in stress-testing for patients with proven CAD whereas 18-F FCPHA is a molecular imaging agent which is designed to assess myocardial blood flow and metabolism in patients with CAD. The company operates in a single segment being Biopharmaceutical research and development.
Executives
Johan M. Spoor director, officer: CEO, PRESIDENT, CHAIRMAN 500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116

FluoroPharma Medical (FluoroPharma Medical) Headlines

From GuruFocus